Key facts
- Neurocentrx’s last known valuation is $9.8M (Sep 2025).
- It has raised $6.2M.
- Notable investors include Scottish Enterprise, Meltwind Advisory, Old College Capital, Wellcome Trust, SPRIM Global Investments — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Neurocentrx
- ·The full record, as it builds
Funding rounds
No funding rounds for Neurocentrx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neurocentrx
Developer of oral delivery medicines designed to treat patients with neurological conditions. The company's medicines are oral ketamine formulations that treat central nervous system conditions and cancer-related pain, enabling patients to alleviate severe and chronic neuropathic pain conditions.
- Sector
- Healthcare
- HQ
- Edinburgh, United Kingdom
- Founded
- 2013
- Employees
- 6
- Website
- neurocentrx.com/
- Ownership
- Privately Held (backing)
Neurocentrx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neurocentrx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neurocentrx in its N-PORT filings yet. We sweep new filings monthly.